Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers.

Finkelmeier F, Czauderna C, Perkhofer L, Ettrich TJ, Trojan J, Weinmann A, Marquardt JU, Vermehren J, Waidmann O.

J Cancer Res Clin Oncol. 2018 Oct 29. doi: 10.1007/s00432-018-2780-8. [Epub ahead of print]

PMID:
30374657
2.

Nivolumab for the treatment of hepatocellular carcinoma.

Finkelmeier F, Waidmann O, Trojan J.

Expert Rev Anticancer Ther. 2018 Dec;18(12):1169-1175. doi: 10.1080/14737140.2018.1535315. Epub 2018 Oct 22.

PMID:
30304963
3.

Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.

Walter D, Ferstl P, Waidmann O, Trojan J, Hartmann S, Schnitzbauer AA, Zeuzem S, Kraywinkel K.

Liver Int. 2018 Sep 3. doi: 10.1111/liv.13954. [Epub ahead of print]

PMID:
30176117
4.

Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates.

Koch C, Schmidt N, Winkelmann R, Eichler K, Pession U, Bechstein WO, Zeuzem S, Waidmann O, Trojan J.

Digestion. 2018 Aug 21;98(4):263-269. doi: 10.1159/000490888. [Epub ahead of print]

PMID:
30130797
5.

Risk factors for early and late procedure-related adverse events in percutaneous endoscopic gastrostomy: A single center, retrospective study.

Peveling-Oberhag J, Osman I, Walter D, Filmann N, Stratmann K, Hausmann J, Knop V, Waidmann O, Vermehren J, Herrmann E, Zeuzem S, Friedrich-Rust M, Blumenstein I, Albert JG.

J Gastroenterol Hepatol. 2018 Aug 2. doi: 10.1111/jgh.14407. [Epub ahead of print] No abstract available.

PMID:
30070394
6.

Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis.

Finkelmeier F, Canli Ö, Peiffer KH, Walter D, Tal A, Koch C, Pession U, Vermehren J, Trojan J, Zeuzem S, Piiper A, Greten FR, Grammatikos G, Waidmann O.

PLoS One. 2018 Jul 16;13(7):e0200855. doi: 10.1371/journal.pone.0200855. eCollection 2018.

7.

Recent developments with immunotherapy for hepatocellular carcinoma.

Waidmann O.

Expert Opin Biol Ther. 2018 Aug;18(8):905-910. doi: 10.1080/14712598.2018.1499722. Epub 2018 Jul 20.

PMID:
29995439
8.

Sequence therapy in metastatic pancreatic cancer.

Waidmann O, Pelzer U, Boeck S, Waldschmidt DT.

Z Gastroenterol. 2018 Jun;56(6):578-582. doi: 10.1055/a-0581-5640. Epub 2018 Jun 11.

PMID:
29890560
9.

Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals.

Finkelmeier F, Dultz G, Peiffer KH, Kronenberger B, Krauss F, Zeuzem S, Sarrazin C, Vermehren J, Waidmann O.

Liver Cancer. 2018 May;7(2):190-204. doi: 10.1159/000486812. Epub 2018 Mar 1.

10.

Activation of Adenylyl Cyclase Causes Stimulation of Adenosine Receptors.

Pleli T, Mondorf A, Ferreiros N, Thomas D, Dvorak K, Biondi RM, Heringdorf DMZ, Zeuzem S, Geisslinger G, Zimmermann H, Waidmann O, Piiper A.

Cell Physiol Biochem. 2018;45(6):2516-2528. doi: 10.1159/000488270. Epub 2018 Mar 27.

11.

PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells.

Raab M, Sanhaji M, Matthess Y, Hörlin A, Lorenz I, Dötsch C, Habbe N, Waidmann O, Kurunci-Csacsko E, Firestein R, Becker S, Strebhardt K.

Nat Commun. 2018 Mar 16;9(1):1106. doi: 10.1038/s41467-018-03494-4.

12.

Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors.

Walter D, Harter PN, Battke F, Winkelmann R, Schneider M, Holzer K, Koch C, Bojunga J, Zeuzem S, Hansmann ML, Peveling-Oberhag J, Waidmann O.

Sci Rep. 2018 Feb 28;8(1):3811. doi: 10.1038/s41598-018-22115-0.

13.

Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE.

Khageh Hosseini S, Kolterer S, Steiner M, von Manstein V, Gerlach K, Trojan J, Waidmann O, Zeuzem S, Schulze JO, Hahn S, Steinhilber D, Gatterdam V, Tampé R, Biondi RM, Proschak E, Zörnig M.

Biochem Pharmacol. 2017 Dec 15;146:53-62. doi: 10.1016/j.bcp.2017.10.003. Epub 2017 Oct 13.

PMID:
29031818
14.

Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study.

Kolly P, Waidmann O, Vermehren J, Moreno C, Vögeli I, Berg T, Semela D, Zeuzem S, Dufour JF.

J Hepatol. 2017 Oct;67(4):876-878. doi: 10.1016/j.jhep.2017.07.007. Epub 2017 Jul 19. No abstract available.

PMID:
28733219
15.

Update on cholangiocarcinoma: potential impact of genomic studies on clinical management.

Walter D, Hartmann S, Waidmann O.

Z Gastroenterol. 2017 Jun;55(6):575-581. doi: 10.1055/s-0043-102581. Epub 2017 Apr 4. Review.

PMID:
28376540
16.

The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease.

Ferstl PG, Filmann N, Brandt C, Zeuzem S, Hogardt M, Kempf VAJ, Müller M, Waidmann O, Reinheimer C.

Liver Int. 2017 Oct;37(10):1488-1496. doi: 10.1111/liv.13438. Epub 2017 May 20.

PMID:
28374901
17.

Severe infection with multidrug-resistant Salmonella choleraesuis in a young patient with primary sclerosing cholangitis.

Ferstl PG, Reinheimer C, Jozsa K, Zeuzem S, Kempf VA, Waidmann O, Grammatikos G.

World J Gastroenterol. 2017 Mar 21;23(11):2086-2089. doi: 10.3748/wjg.v23.i11.2086.

18.

Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial-Mesenchymal Transition.

Ibrahim AA, Schmithals C, Kowarz E, Köberle V, Kakoschky B, Pleli T, Kollmar O, Nitsch S, Waidmann O, Finkelmeier F, Zeuzem S, Korf HW, Schmid T, Weigert A, Kronenberger B, Marschalek R, Piiper A.

Clin Cancer Res. 2017 Jul 15;23(14):3896-3905. doi: 10.1158/1078-0432.CCR-16-1762. Epub 2017 Feb 6.

19.

Reply to the Letter to the Editor concerning 'High levels of the soluble programmed death-ligand identify hepatocellular carcinoma patients with a poor prognosis'.

Finkelmeier F, Waidmann O.

Eur J Cancer. 2017 Jan;71:119-120. doi: 10.1016/j.ejca.2016.10.027. Epub 2016 Dec 15. No abstract available.

PMID:
27989635
20.

To treat or not to treat - Successful hepatitis C virus eradication in a patient with advanced hepatocellular carcinoma and complete response to sorafenib.

Waidmann O, Peveling-Oberhag J, Eichler K, Schulze F, Vermehren J.

Z Gastroenterol. 2017 Jun;55(6):564-568. doi: 10.1055/s-0042-118232. Epub 2016 Nov 2.

PMID:
27806410
21.
22.

High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.

Finkelmeier F, Canli Ö, Tal A, Pleli T, Trojan J, Schmidt M, Kronenberger B, Zeuzem S, Piiper A, Greten FR, Waidmann O.

Eur J Cancer. 2016 May;59:152-159. doi: 10.1016/j.ejca.2016.03.002. Epub 2016 Mar 31.

PMID:
27039170
23.

Cytokeratin 18-based cell death markers indicate severity of liver disease and prognosis of cirrhotic patients.

Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B.

Liver Int. 2016 Oct;36(10):1464-72. doi: 10.1111/liv.13117. Epub 2016 Apr 4.

PMID:
26991828
24.

Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma.

Grammatikos G, Schoell N, Ferreirós N, Bon D, Herrmann E, Farnik H, Köberle V, Piiper A, Zeuzem S, Kronenberger B, Waidmann O, Pfeilschifter J.

Oncotarget. 2016 Apr 5;7(14):18095-105. doi: 10.18632/oncotarget.7741.

25.

Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis.

Finkelmeier F, You SJ, Waidmann O, Wolff R, Zeuzem S, Bähr O, Trojan J.

J Gastrointest Cancer. 2016 Mar;47(1):82-8. doi: 10.1007/s12029-015-9795-z.

PMID:
26714801
26.

Vesicle-associated microRNAs are released from blood cells on incubation of blood samples.

Köberle V, Kakoschky B, Ibrahim AA, Schmithals C, Peveling-Oberhag J, Zeuzem S, Kronenberger B, Waidmann O, Pleli T, Piiper A.

Transl Res. 2016 Mar;169:40-6. doi: 10.1016/j.trsl.2015.10.010. Epub 2015 Nov 5.

PMID:
26608461
27.

The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients.

Dultz G, Gerber L, Zeuzem S, Sarrazin C, Waidmann O.

J Viral Hepat. 2016 Apr;23(4):267-73. doi: 10.1111/jvh.12488. Epub 2015 Nov 10.

PMID:
26554542
28.

[New insights into epidemiology may promote screening in Cholangiocarcinoma].

Albert JG, Waidmann O, Welzel TM.

Dtsch Med Wochenschr. 2015 Sep;140(19):1431-4. doi: 10.1055/s-0041-105627. Epub 2015 Sep 24. German.

PMID:
26402178
29.

Serum Sphingolipid Variations Associate with Hepatic Decompensation and Survival in Patients with Cirrhosis.

Grammatikos G, Ferreiròs N, Waidmann O, Bon D, Schroeter S, Koch A, Herrmann E, Zeuzem S, Kronenberger B, Pfeilschifter J.

PLoS One. 2015 Sep 18;10(9):e0138130. doi: 10.1371/journal.pone.0138130. eCollection 2015.

30.

Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.

Schmithals C, Köberle V, Korkusuz H, Pleli T, Kakoschky B, Augusto EA, Ibrahim AA, Arencibia JM, Vafaizadeh V, Groner B, Korf HW, Kronenberger B, Zeuzem S, Vogl TJ, Waidmann O, Piiper A.

Cancer Res. 2015 Aug 1;75(15):3147-54. doi: 10.1158/0008-5472.CAN-15-0395.

31.

Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in Patients with Cirrhosis.

Finkelmeier F, Kronenberger B, Zeuzem S, Piiper A, Waidmann O.

PLoS One. 2015 Jun 29;10(6):e0132119. doi: 10.1371/journal.pone.0132119. eCollection 2015.

32.

Novel drugs in clinical development for hepatocellular carcinoma.

Waidmann O, Trojan J.

Expert Opin Investig Drugs. 2015;24(8):1075-82. doi: 10.1517/13543784.2015.1058776. Epub 2015 Jun 24. Review.

PMID:
26108356
33.

ERCP in elderly patients: increased risk of sedation adverse events but low frequency of post-ERCP pancreatitis.

Finkelmeier F, Tal A, Ajouaou M, Filmann N, Zeuzem S, Waidmann O, Albert J.

Gastrointest Endosc. 2015 Dec;82(6):1051-9. doi: 10.1016/j.gie.2015.04.032. Epub 2015 Jun 16.

PMID:
26089104
34.

Endoscopic findings in patients with eosinophilic esophagitis.

Waidmann O, Finkelmeier F, Welker MW, Sprinzl K, Zeuzem S, Albert JG.

Z Gastroenterol. 2015 May;53(5):379-84. doi: 10.1055/s-0034-1385767. Epub 2015 May 12.

PMID:
25965984
35.

Letter: proton pump inhibitor treatment and increased mortality in cirrhotic patients--authors' reply.

Dultz G, Piiper A, Zeuzem S, Kronenberger B, Waidmann O.

Aliment Pharmacol Ther. 2015 Jun;41(11):1225. doi: 10.1111/apt.13207. No abstract available.

36.

Letter: proton pump inhibitors - severity of liver disease and mortality in patients with cirrhosis - authors' reply.

Dultz G, Piiper A, Zeuzem S, Kronenberger B, Waidmann O.

Aliment Pharmacol Ther. 2015 Apr;41(7):706. doi: 10.1111/apt.13110. No abstract available.

37.

The E3 ubiquitin ligase parkin is recruited to the 26 S proteasome via the proteasomal ubiquitin receptor Rpn13.

Aguileta MA, Korac J, Durcan TM, Trempe JF, Haber M, Gehring K, Elsasser S, Waidmann O, Fon EA, Husnjak K.

J Biol Chem. 2015 Mar 20;290(12):7492-505. doi: 10.1074/jbc.M114.614925. Epub 2015 Feb 9.

38.

Colonisation with multidrug-resistant bacteria is associated with increased mortality in patients with cirrhosis.

Waidmann O, Kempf VA, Brandt C, Zeuzem S, Piiper A, Kronenberger B.

Gut. 2015 Jul;64(7):1183-4. doi: 10.1136/gutjnl-2014-309104. Epub 2015 Jan 23. No abstract available.

PMID:
25616276
39.

Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis.

Dultz G, Piiper A, Zeuzem S, Kronenberger B, Waidmann O.

Aliment Pharmacol Ther. 2015 Mar;41(5):459-66. doi: 10.1111/apt.13061. Epub 2014 Dec 19.

40.

Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging.

Watcharin W, Schmithals C, Pleli T, Köberle V, Korkusuz H, Hübner F, Waidmann O, Zeuzem S, Korf HW, Terfort A, Gelperina S, Vogl TJ, Kreuter J, Piiper A.

J Control Release. 2015 Feb 10;199:63-71. doi: 10.1016/j.jconrel.2014.11.023. Epub 2014 Dec 10.

PMID:
25499552
41.

Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.

Dultz G, Gerber L, Farnik H, Berger A, Vermehren J, Pleli T, Zeuzem S, Piiper A, Kronenberger B, Waidmann O.

J Viral Hepat. 2015 Apr;22(4):427-32. doi: 10.1111/jvh.12309. Epub 2014 Sep 2.

PMID:
25181653
42.

Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis--a prospective cohort study.

Pleli T, Martin D, Kronenberger B, Brunner F, Köberle V, Grammatikos G, Farnik H, Martinez Y, Finkelmeier F, Labocha S, Ferreirós N, Zeuzem S, Piiper A, Waidmann O.

PLoS One. 2014 Jul 25;9(7):e103532. doi: 10.1371/journal.pone.0103532. eCollection 2014.

43.

Commentary: vitamin D deficiency and liver cancer - cause, effect or myth? Authors' reply.

Finkelmeier F, Kronenberger B, Köberle V, Bojunga J, Zeuzem S, Trojan J, Piiper A, Waidmann O.

Aliment Pharmacol Ther. 2014 Jun;39(12):1429-30. doi: 10.1111/apt.12772. No abstract available.

44.

Severe 25-hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma - a prospective cohort study.

Finkelmeier F, Kronenberger B, Köberle V, Bojunga J, Zeuzem S, Trojan J, Piiper A, Waidmann O.

Aliment Pharmacol Ther. 2014 May;39(10):1204-12. doi: 10.1111/apt.12731. Epub 2014 Mar 29.

45.

Single measurement of hemoglobin predicts outcome of HCC patients.

Finkelmeier F, Bettinger D, Köberle V, Schultheiß M, Zeuzem S, Kronenberger B, Piiper A, Waidmann O.

Med Oncol. 2014 Jan;31(1):806. doi: 10.1007/s12032-013-0806-2. Epub 2013 Dec 11.

PMID:
24326985
46.

SEMS vs cSEMS in duodenal and small bowel obstruction: high risk of migration in the covered stent group.

Waidmann O, Trojan J, Friedrich-Rust M, Sarrazin C, Bechstein WO, Ulrich F, Zeuzem S, Albert JG.

World J Gastroenterol. 2013 Oct 7;19(37):6199-206. doi: 10.3748/wjg.v19.i37.6199.

47.

Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers.

Köberle V, Pleli T, Schmithals C, Augusto Alonso E, Haupenthal J, Bönig H, Peveling-Oberhag J, Biondi RM, Zeuzem S, Kronenberger B, Waidmann O, Piiper A.

PLoS One. 2013 Sep 20;8(9):e75184. doi: 10.1371/journal.pone.0075184. eCollection 2013.

48.

Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma.

Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem S, Piiper A, Waidmann O.

Eur J Cancer. 2013 Nov;49(16):3442-9. doi: 10.1016/j.ejca.2013.06.002. Epub 2013 Jun 26.

PMID:
23810247
49.

Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy.

Köberle V, Waidmann O, Kronenberger B, Andrei A, Susser S, Füller C, Perner D, Zeuzem S, Sarrazin C, Piiper A.

J Viral Hepat. 2013 Aug;20(8):530-5. doi: 10.1111/jvh.12075. Epub 2013 Feb 18.

PMID:
23808991
50.

Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.

Waidmann O, Köberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiß M, Kronenberger B, Piiper A.

J Hepatol. 2013 Oct;59(4):769-79. doi: 10.1016/j.jhep.2013.06.008. Epub 2013 Jun 17.

PMID:
23792028

Supplemental Content

Loading ...
Support Center